We are in the middle of the first-quarter 2024 earnings season, with numerous MedTech bigwigs having already released first-quarter results. Per the latest Earnings Preview, quarterly results of the Medical sector are projected to decline year over year, affected by the ongoing macroeconomic headwinds, primarily in the form of worldwide geopolitical issues and healthcare labor shortages. Going by the broader Medical sector’s scorecard, 16.7% of the companies in the Medical sector, constituting 32.6% of the ...

In its upcoming report, Bruker (BRKR) is predicted by Wall Street analysts to post quarterly earnings of $0.46 per share, reflecting a decline of 28.1% compared to the same period last year. Revenues are forecasted to be $723.84 million, representing a year-over-year increase of 5.6%. The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during ...

Bruker Corporation (BRKR) is likely to grow in the coming quarters, backed by the strong potential of the Bruker Scientific Instruments (“BSI”) Nano Group. In BioSpin, strength across end markets, including the new IDS (integrated data solutions) business, sounds encouraging for the company. The CALID Group has also been making decent progress lately, primarily due to the strong demand for differentiated instruments. Meanwhile, exposure to currency fluctuations, as well as competitive challenges, can potent ...

Bruker (BRKR) continues to grow, banking on its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. The stock carries a Zacks Rank #2 (Buy) currently. Bruker’s CALID Group has been making decent progress lately, primarily because of the strong demand for differentiated instruments. The group is benefiting from sustained growth in the mass spectrometry business, including FT-IR, Near IR and Raman molecular spectroscopy product lines. Bruker’s timsTOF platform con ...

NanoString’s GeoMX Digital Spatial Profiler was at the heart of a patent lawsuit filed by 10x Genomics. (NanoString Image) NanoString announced Wednesday that it will be acquired by Bruker, ending the company’s restructuring process that included a Chapter 11 bankruptcy plan. Bruker, a Massachusetts-based publicly traded life sciences research and diagnostic giant founded in 1960, will pay $392.6 million to buy Seattle-based NanoString. The deal is expected to close next month. NanoString said in February t ...

Bruker Corporation (BRKR) introduced novel magnet technology and analytical solutions at the 65th ENC. The novel technology facilitates the widespread application of NMR in academic basic and clinical research, as well as in drug discovery and development by biopharmacies and process analytical technologies (PAT). The latest development will fortify Bruker’s Scientific Instruments (BSI) BioSpin segment. More on New Magnet Technology At the 65th ENC, with a complete one-year liquid helium hold-time, more tha ...

合作关系 - Biognosys和Alamar将在非小细胞肺癌研究方面展开合作[1] - Biognosys和Alamar将共同开展研究合作，探索血浆生物学[3] 服务提供 - Biognosys将提供NULISA Assay Services，为研究人员提供有价值的生物过程洞察[2] 技术创新 - Biognosys和Alamar的合作旨在推动蛋白质组学研究，为精准医学提供创新技术[4]

Shares of Bruker Corporation (BRKR) reached a new 52-week high of $94.86 on Mar 21 before closing the session marginally lower at $94.27. In the past year, this Zacks Rank #3 (Hold) stock has risen 25.9% against a 1.1% decline of the industry and the S&P 500 composite’s rise of 32.2%. Over the past five years, Bruker registered earnings growth of 13%, comparing favorably with the industry’s 5.1% rise. The company has an expected long-term earnings growth rate of 14.4%. Bruker’s earnings surpassed the Zacks ...

PharmaVentures与Phasefocus Holdings Limited合作 - PharmaVentures作为Phasefocus Holdings Limited的独家顾问，协助其被Bruker收购[1] - PharmaVentures的董事Adrian Dawkes表示，此次交易为Phasefocus股东带来了成功的结果，获得了Bruker的商业认可[3] Phasefocus的业务和产品 - Phasefocus是一家专注于成像、图像处理算法和成像平台的私人公司[2] - Phasefocus开发了一种名为Livecyte的新型光学显微镜[2]

It has been about a month since the last earnings report for Bruker (BRKR) . Shares have added about 15.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Bruker Q4 Earnings Top Estimates, Margins Fall Bruker C ...